Back to News
investment

Siga Technologies: No News (On BARDA Contract) Not Necessarily Good News

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
SIGA Technologies faces revenue uncertainty as its sole product, TPOXX, depends on a pending U.S. BARDA contract renewal, with no updates since December 2025. 2025 revenues fell from 2024, leaving just $26 million in remaining BARDA orders and a $13 million Asia-Pacific deal for 2026, signaling shrinking demand. Regulatory hurdles for TPOXX’s Mpox use and weak international sales deepen reliance on U.S. government procurement, raising long-term viability concerns. Despite $155 million in cash and no debt, the company’s future hinges on BARDA’s decision, with no clear revenue streams beyond existing contracts. Analysts maintain a "Hold" rating, citing a 10% stock drop since December and over 60% decline since a prior "Buy" recommendation.
AI Audio Summary
0:00 / 0:00
Click to play
Generate images of quantum computing to be used as banner image for articles.jpg
Quantum News · Media Library

Edmund InghamInvesting Group LeaderFollow5ShareSavePlay(11min)CommentsSummarySIGA Technologies, Inc. remains a Hold as future revenue may hinge on BARDA contract renewal for TPOXX, its sole commercial product.SIGA's 2025 revenues declined versus 2024, with potentially only $26m in remaining BARDA orders and a $13m Asia Pacific order secured for 2026.Regulatory setbacks in Mpox indications and lack of significant non-U.S. buyers heighten dependence on U.S. government procurement.While SIGA holds $155m cash and no debt, absent a new BARDA contract, long-term revenue visibility and upside remain highly uncertain.Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios. Learn More » Hailshadow/iStock via Getty Images Investment Overview SIGA Technologies, Inc. (SIGA) stock is down nearly 10% since I last covered the company in December last year, issuing a Hold recommendation, and now down >60% since I gave stock a Buy rating backThis article was written byEdmund Ingham14.84K FollowersFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Read Original

Tags

quantum-market

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.